Following its announcement on the 28th January, Immunodiagnostic Systems Holdings plc (“IDS” or “the Company”), a leading producer of diagnostic testing kits for the clinical and research markets, announces the launch of its new fully-automated immunoanalyser, the IDS-iSYS and at the same time the launch of its automated IDS-iSYS Vitamin D assay.
IDS’s automated version of its flagship product, 25 Hydroxy Vitamin D, a test to quantify vitamin D in patient serum or plasma, was CE marked on Friday 27th February and is now available for sale on its fully-automated immunoanalyser, the IDS-iSYS.
Demand for vitamin D testing has been growing strongly in recent times due to the increasing awareness of the importance of ‘adequacy’ in vitamin D in reducing predisposition to numerous disease conditions, including common cancers (colon, breast and prostate) and autoimmune disease, as well as the long accepted role in building strong bones and teeth.
Additional diagnostic products in the field of Bone & Skeletal health and Growth Regulation will be launched during the year as the Company continues to develop and expand its range of automated products available on the IDS-iSYS.
The Chief Executive Officer, Dr Roger Duggan, commented: “The launch of the IDS-iSYS represents a milestone in the Company’s history, and follows a period of intense activity throughout the entire IDS Group. Automation of our highly specialized diagnostic products will take us into much larger and more prestigious clinical and corporate laboratories, accounts that were hitherto beyond our reach. The global IDS team has done a great job in bringing to fruition the launch of Vitamin D on the IDS-iSYS following our acquisition of the technology in late 2007.”
For more information, please visit click here